Uruguay: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Uruguay

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Uruguay: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Subscribe to access the full database, or Start Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
SIGNIFOR LAR	pasireotide pamoate	2027-05-24
LASTACAFT	alcaftadine	2027-04-02
BRILINTA	ticagrelor	2027-08-20
SIRTURO	bedaquiline fumarate	2027-12-05
TRADJENTA	linagliptin	2027-05-03
LIVDELZI	seladelpar lysine	2026-09-14
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Uruguay: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Uruguay Patent 31,103

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

When can LASTACAFT (alcaftadine) generic drug versions launch?

Generic name: alcaftadine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 02, 2027
Generic Entry Controlled by: Uruguay Patent 30,254

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

When can BRILINTA (ticagrelor) generic drug versions launch?

Generic name: ticagrelor
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 20, 2027
Generic Entry Controlled by: Uruguay Patent 30,551

BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-eight suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch?

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2027
Generic Entry Controlled by: Uruguay Patent 30,762

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

When can TRADJENTA (linagliptin) generic drug versions launch?

Generic name: linagliptin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Uruguay Patent 30,319

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

When can LIVDELZI (seladelpar lysine) generic drug versions launch?

Generic name: seladelpar lysine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 14, 2026
Generic Entry Controlled by: Uruguay Patent 29,791

LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-six countries.

The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch?

Generic name: copanlisib dihydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2027
Generic Entry Controlled by: Uruguay Patent 30,761

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-eight countries.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.